Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - U.S.-based Merck and China's Sinopharm plan to work together to develop vaccines in China under a preliminary deal that could ultimately see Sinopharm marketing more of the pharmaceutical giant's products in Asia's most populous nation

You may also be interested in...



Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?

Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from a partnership with Sinopharm it had previously emphasized.

Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?

Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from an intended partnership with Sinopharm it had previously emphasized.

Merck’s Emerging Markets R&D Head RuiPing Dong On Developing Drugs To Meet Local Needs: An Interview With PharmAsia News (Part 2 of 2)

Merck discusses its R&D strategy in emerging markets; the company announced last week the largest ever R&D investment in China for a pharmaceutical company.

Related Content

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel